EP4364727A3 - Adenosine receptor antagonists and uses thereof - Google Patents

Adenosine receptor antagonists and uses thereof Download PDF

Info

Publication number
EP4364727A3
EP4364727A3 EP24152200.2A EP24152200A EP4364727A3 EP 4364727 A3 EP4364727 A3 EP 4364727A3 EP 24152200 A EP24152200 A EP 24152200A EP 4364727 A3 EP4364727 A3 EP 4364727A3
Authority
EP
European Patent Office
Prior art keywords
adenosine receptor
receptor antagonists
adenosine
modulating
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24152200.2A
Other languages
German (de)
French (fr)
Other versions
EP4364727A2 (en
Inventor
Jiwen Liu
Elfatih Elzein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teon Therapeutics Inc
Original Assignee
Teon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teon Therapeutics Inc filed Critical Teon Therapeutics Inc
Publication of EP4364727A2 publication Critical patent/EP4364727A2/en
Publication of EP4364727A3 publication Critical patent/EP4364727A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.
EP24152200.2A 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof Pending EP4364727A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US201862688088P 2018-06-21 2018-06-21
EP19764343.0A EP3762386B1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP19764343.0A Division EP3762386B1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
EP4364727A2 EP4364727A2 (en) 2024-05-08
EP4364727A3 true EP4364727A3 (en) 2024-05-15

Family

ID=67847428

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19764343.0A Active EP3762386B1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof
EP24152200.2A Pending EP4364727A3 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19764343.0A Active EP3762386B1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Country Status (12)

Country Link
US (3) US20210040097A1 (en)
EP (2) EP3762386B1 (en)
JP (2) JP2021517164A (en)
KR (1) KR20200132901A (en)
CN (1) CN112218867B (en)
AU (1) AU2019232736B2 (en)
BR (1) BR112020018158A2 (en)
CA (1) CA3093234A1 (en)
IL (1) IL277144B2 (en)
MX (1) MX2020009286A (en)
SG (1) SG11202008611UA (en)
WO (1) WO2019173380A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173380A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
MX2023001571A (en) * 2020-08-07 2023-04-13 Teon Therapeutics Inc Combination therapy with adenosine receptor antagonists.
US20230365564A1 (en) * 2020-09-04 2023-11-16 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist
WO2022256550A1 (en) 2021-06-04 2022-12-08 Teon Therapeutics, Inc. Crystalline forms of an adenosine a2b receptor antagonist
TW202327612A (en) * 2021-09-10 2023-07-16 美商天恩治療有限公司 Improved therapy with adenosine receptor antagonists
WO2024015372A1 (en) * 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
WO1999052903A1 (en) * 1998-04-15 1999-10-21 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
GEP20074230B (en) * 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
ATE403656T1 (en) * 2003-05-06 2008-08-15 Cv Therapeutics Inc XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS
MX2007002437A (en) 2004-09-01 2007-08-14 Cv Therapeutics Inc Method of wound healing using a2b adenosine receptor antagonists.
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
NZ571324A (en) 2006-03-17 2011-07-29 Gilead Palo Alto Inc Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists
US20100254965A1 (en) 2006-10-24 2010-10-07 Board Of Regents ,The University Of Texas System Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
JP5848761B2 (en) * 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
EA201291274A1 (en) * 2010-06-30 2013-12-30 Джилид Сайэнс, Инк. APPLICATION OF ANTAGONISTS OF ADENOSINE RECEPTORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
AU2011303420B2 (en) * 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
AR085942A1 (en) 2011-04-07 2013-11-06 Gilead Sciences Inc USE OF AADENOSINE RECEPTOR TO TREAT CARDIAC INSUFFICIENCY AND ARRITMIA IN POST-INFAR PATIENTS OF MYOCARDIUM
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
EP3668517A4 (en) 2017-08-14 2021-02-17 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
US10709763B2 (en) 2017-12-19 2020-07-14 Gpcr Therapeutics, Inc. GPCR heteromer inhibitors and uses thereof
WO2019173380A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138376A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists

Also Published As

Publication number Publication date
US11124515B2 (en) 2021-09-21
CA3093234A1 (en) 2019-09-12
IL277144B1 (en) 2024-02-01
EP3762386A1 (en) 2021-01-13
US20220056033A1 (en) 2022-02-24
EP4364727A2 (en) 2024-05-08
AU2019232736B2 (en) 2024-05-02
KR20200132901A (en) 2020-11-25
EP3762386B1 (en) 2024-01-24
JP2021517164A (en) 2021-07-15
CN112218867A (en) 2021-01-12
US20210040097A1 (en) 2021-02-11
BR112020018158A2 (en) 2021-02-02
IL277144A (en) 2020-10-29
IL277144B2 (en) 2024-06-01
US20210163483A1 (en) 2021-06-03
SG11202008611UA (en) 2020-10-29
CN112218867B (en) 2023-11-21
JP2024032976A (en) 2024-03-12
MX2020009286A (en) 2020-12-11
AU2019232736A1 (en) 2020-10-08
EP3762386A4 (en) 2021-11-24
WO2019173380A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
EP4364727A3 (en) Adenosine receptor antagonists and uses thereof
EP3762385A4 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
EP3758671A4 (en) Natural 1,2-alkanediols, compositions having natural 1,2-alkanediols and processes for making the same
EP3765522A4 (en) Anti-claudin 18.2 antibodies
EP3867250A4 (en) Conjugation linkers containing 2,3-diaminosuccinyl group
EP3898922A4 (en) Solvent compositions containing 1,2,2-trifluoro-1-trifluoromethylcyclobutane (tfmcb)
CN107397757A8 (en) Lubricant formulations
EP4017883A4 (en) Novel anti-cldn18.2 antibodies
EP3894398A4 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
EP3774027A4 (en) Electrocatalysts, the preparation thereof, and using the same for ammonia synthesis
WO2019089676A8 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3880194A4 (en) Deuterated compounds, compositions, and uses
DK3752490T3 (en) HERBICIDE 3-AZASPIRO [5.5] UNDECAN-8,10-DION COMPOUNDS
EP3760195A4 (en) Composition comprisng 2,3-butanediol as active ingredient
EP3911355A4 (en) Recombinant lubricins, and compositions and methods for using the same
IL290882A (en) Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
EP3911324A4 (en) 1,8-naphthyridinone compounds and uses thereof
EP3947466A4 (en) Anti-hla-dq2.5 antibody
EP3793550A4 (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
EP3888043A4 (en) Crowdfunding 4.0: a novel influence-based global fundraising platform and system
EP3983448A4 (en) Soluble complement receptor type 1 variant conjugates and uses thereof
LT3923914T (en) Afabicin formulation, method for making the same
EP3793586A4 (en) Soluble complement receptor type 1 variants and uses thereof
EP4007578A4 (en) Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
WO2020021341A8 (en) Compositions for the treatment of hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009480000

Ipc: C07D0473060000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 3762386

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20240408BHEP

Ipc: A61K 9/20 20060101ALI20240408BHEP

Ipc: A61K 31/661 20060101ALI20240408BHEP

Ipc: A61K 31/522 20060101ALI20240408BHEP

Ipc: A61P 35/00 20060101ALI20240408BHEP

Ipc: A61P 25/00 20060101ALI20240408BHEP

Ipc: A61P 13/12 20060101ALI20240408BHEP

Ipc: A61P 11/00 20060101ALI20240408BHEP

Ipc: A61P 9/00 20060101ALI20240408BHEP

Ipc: A61P 3/10 20060101ALI20240408BHEP

Ipc: A61P 3/04 20060101ALI20240408BHEP

Ipc: A61P 1/16 20060101ALI20240408BHEP

Ipc: C07F 9/6561 20060101ALI20240408BHEP

Ipc: C07D 473/06 20060101AFI20240408BHEP